CSIMarket
 
Hexo Corp   (HEXO)
Other Ticker:  
 
 
Price: $0.7100 $0.02 2.899%
Day's High: $0.71 Week Perf: -7.31 %
Day's Low: $ 0.66 30 Day Perf: -50.35 %
Volume (M): 306 52 Wk High: $ 1.92
Volume (M$): $ 217 52 Wk Avg: $1.18
Open: $0.67 52 Wk Low: $0.66



 Market Capitalization (Millions $) 220
 Shares Outstanding (Millions) 310
 Employees -
 Revenues (TTM) (Millions $) 62
 Net Income (TTM) (Millions $) -419
 Cash Flow (TTM) (Millions $) 87
 Capital Exp. (TTM) (Millions $) 0

Hexo Corp
Hexo Corp is a Canadian cannabis company that specializes in producing and distributing recreational and medical cannabis products. They were founded in 2013 and are headquartered in Gatineau, Quebec. Hexo Corp focuses on innovation and sustainability in their cultivation and manufacturing processes, utilizing advanced technology and environmentally friendly practices. They have a diverse product portfolio, offering a range of cannabis flower, oils, edibles, and beverages under various brand names.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Chromadex Corporation

Legal Cannabis Company Surpasses Expectations in Fourth Quarter Earnings

CDXC, also known as ChromaDex Corporation, recently achieved a break-even point with a moderate increase in revenue. In the most recent fiscal period, their revenue rose by 0.953% to $21.20 million compared to the corresponding quarter a year prior. While this may seem positive, it is crucial to understand how CDXC performed in relation to its competitors in the legal cannabis industry. Unfortunately, CDXC underperformed in comparison to its contemporaries, who reported a business advance of 4.20% from the same quarter a year ago.
The previous quarter showed some improvement for CDXC, as their revenue increased by 8.725% from $19.50 million. Additionally, they achieved earnings of $0.114 million in the most recent fiscal period, a significant improvement compared to a net shortfall of $-1.418 million in the same quarter a year ago. Despite these positive aspects, CDXC's stockpiles have increased to $14.5 million, lower than the previous year's level of $14.7 million. Additionally, their accounts receivable has declined to $5.2 million, potentially indicating slowing demand.

Usana Health Sciences Inc

Usana Health Sciences Inc Sees Profits Surge Despite Revenue Dip

Despite a slight decrease in revenue during the October to December 2023 period, Usana Health Sciences Inc (USNA) managed to raise its earnings per share (EPS), showing significant growth in profit. The company reported a surge of 30.06% in profit per share to $0.87, while revenue fell by -2.722% to $221.76 million year on year.
Comparing these results with the prior financial reporting period, Usana Health Sciences Inc demonstrated impressive growth. EPS soared from $0.59 per share, and revenue advanced by 4.195% from $212.84 million. This shows that the company is continuing to increase its profitability, even in the face of slightly lower revenue.
Furthermore, Usana Health Sciences Inc highlighted its improving profit margins, with net margin rising to 7.56% and operating margin edging up to 10.92% during the October to December 2023 period. These figures indicate the company's ability to control costs and maximize its profitability.

Alterola Biotech Inc

Operating Losses Surge for Alterola Biotech Inc in Q4 2023 Financial Report

Alterola Biotech Inc, a legal cannabis company, has recently released its financial report for the October to December 2023 reporting cycle. The shareholders have not anticipated any changes in revenue during this period. However, they have expressed concerns over the company's operating loss, which amounted to $-1.108947 million.
To better understand the current state of the company, it is important to compare its performance with previous quarters. In the third quarter of 2023, Alterola Biotech Inc reported an operating loss of $0.540621 million. This indicates a significant increase in losses during the October to December 2023 reporting cycle.

Natural Alternatives International Inc

Natural Alternatives International Inc. Struggles with Serious Deterioration in Revenue during Second Quarter of 2024 Earnings Season

The financial results of Natural Alternatives International Inc. for the second quarter of 2024 paint a challenging picture for the company. The significant deficit per share, declining revenue, and net loss compared to the previous year all point towards a tough period for the company.
One key highlight from the results is the decline in inventories and the increase in accounts receivable. The decrease in inventories could indicate lower expected demand for the company's products, while the rise in accounts receivable could suggest an increase in sales but delayed payments. These factors can have implications for the company's future performance and growth prospects.

Upexi Inc

Upexi Inc Faces Unexpected Revenue Contraction, Amidst Second Quarter of 2024 Earnings Season

Upexi Inc, a leading player in the legal cannabis sector, has recently posted disappointing financial results for the most recent fiscal period. Despite these challenges, there are signs of potential growth and improvement on the horizon.
While the company reported a loss per share of $-0.12, a decline from the previous year, it is important to note that the legal cannabis sector as a whole has seen a 32.13% increase in revenue compared to the same period a year before. This indicates that there is still strong demand and opportunity in the industry, and Upexi Inc is well positioned to capitalize on this growth.






 

Hexo's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com